Ameloblastoma is a rare, slow-growing tumor that forms in the jawbone from cells left over after teeth develop. It is classified as benign, meaning it doesn’t spread to distant parts of the body in the vast majority of cases, but it behaves aggressively where it grows, gradually destroying bone and expanding into surrounding tissue. About 92% of cases occur in the lower jaw, and the average age at diagnosis is around 35.
Where Ameloblastoma Comes From
Your teeth form through a complex process that involves specialized cells called ameloblasts. These cells produce enamel during development and are supposed to disappear once the tooth is fully formed. But small clusters of leftover cells can persist in the jawbone and in the tissues around tooth roots. Ameloblastoma develops when these remnant cells begin to grow abnormally, forming a mass of proliferating tissue within the bone.
The tumor can also arise from the lining of existing jaw cysts, particularly dentigerous cysts (fluid-filled sacs that form around unerupted teeth). In some cases, a previously harmless cyst undergoes changes that transform it into an ameloblastoma. Despite its aggressive local behavior, the tumor does not produce hard tissue like enamel or bone on its own. It grows as soft tissue islands, strands, and cords embedded within a fibrous framework.
Types of Ameloblastoma
The World Health Organization recognizes four main types, each with different characteristics and behavior.
- Conventional ameloblastoma accounts for roughly 91% of cases. It grows within the bone as a solid or multicystic mass and has the highest tendency to recur after treatment. Several histological patterns exist within this category, including follicular, plexiform, and desmoplastic variants, though these distinctions matter more to pathologists than to patients.
- Unicystic ameloblastoma makes up about 6% of cases and is the type most commonly seen in younger patients and teenagers. It presents as a single cyst-like cavity in the jaw and generally has a better prognosis than conventional ameloblastoma.
- Peripheral ameloblastoma represents roughly 2% of cases. Unlike the other types, it grows in the gum tissue rather than inside the bone. It typically appears as a painless, slow-growing swelling on the gums and is the least aggressive form.
- Metastasizing ameloblastoma is extremely rare. It looks identical to a benign ameloblastoma under the microscope but has somehow spread to distant sites, most often the lungs.
Symptoms and Warning Signs
Ameloblastoma is often asymptomatic in its early stages, which is one reason it can grow for months or years before being detected. Many cases are discovered incidentally on dental X-rays taken for other reasons. As the tumor enlarges, the most common sign is a painless swelling or lump in the jaw that gradually changes the shape of your face.
Over time, teeth near the tumor may become loose or shift position. You might notice that a tooth seems to be pushed out of alignment or that your bite feels different. In more advanced cases, the tumor can cause numbness or tingling in the lower lip and chin by pressing on the nerve that runs through the lower jaw. Pain is uncommon early on but can develop as the mass grows larger and stretches the surrounding bone.
How It Looks on Imaging
On X-rays and CT scans, ameloblastoma appears as a dark (radiolucent) area within the jawbone, indicating that normal bone has been replaced by softer tumor tissue. Smaller tumors may look like a single rounded dark spot, which can be confused with a simple cyst. Larger tumors often develop internal bony ridges that create a characteristic “soap bubble” or “honeycomb” pattern on imaging.
The tumor also tends to cause root resorption, meaning it gradually dissolves the roots of nearby teeth and can push teeth deeper into the bone. These features help distinguish ameloblastoma from other jaw lesions, but imaging alone isn’t enough for a definitive diagnosis. Odontogenic keratocysts, another type of jaw cyst, can look similar on X-rays. One distinguishing feature is density: ameloblastoma tissue is denser, closer to muscle tissue on CT scans, while keratocysts are fluid-filled and appear less dense. A tissue biopsy is ultimately needed to confirm the diagnosis.
Genetic Drivers
Research has identified specific genetic mutations that fuel ameloblastoma growth, and they differ depending on where in the jaw the tumor develops. About 75% of ameloblastomas in the lower jaw carry a mutation called BRAF V600E, which is the same mutation found in certain skin cancers and brain tumors. It causes a signaling protein to stay permanently switched on, driving uncontrolled cell growth.
Tumors in the upper jaw follow a different pathway. Only about 30% of maxillary ameloblastomas carry the BRAF mutation. Instead, they more commonly have mutations in a gene called SMO, which is part of a separate growth signaling system. This distinction suggests that ameloblastomas in the upper and lower jaw may develop through fundamentally different biological mechanisms, which could eventually influence treatment choices.
Treatment Options and Recurrence
Surgery is the primary treatment for ameloblastoma, but the extent of surgery depends on the tumor type and size. The central challenge is balancing complete tumor removal against preserving jaw function and appearance.
Conservative approaches like curettage (scraping the tumor out) or enucleation (scooping it out as a whole) are less invasive and preserve more bone. However, recurrence rates with these methods are high: 55 to 90% of conventionally treated tumors eventually come back. After conservative treatment, the expected recurrence-free survival rate at 10 years drops to just 36%.
Radical surgery, which involves removing the tumor along with a margin of healthy bone around it, dramatically lowers recurrence. The 10-year recurrence-free survival rate with radical treatment is approximately 80%, and overall recurrence rates fall to 15 to 25%. The tradeoff is significant: removing a section of the jaw creates functional and cosmetic challenges that require reconstructive surgery.
Unicystic ameloblastoma is more forgiving. With aggressive surgical treatment, recurrence drops to around 11%, and even conservative treatment yields a recurrence rate of about 20%, making it more amenable to less invasive approaches, particularly in younger patients.
Jaw Reconstruction After Surgery
When a significant portion of the jaw is removed, reconstruction is typically performed during the same surgery or shortly afterward. The most common technique uses a section of bone from your lower leg (the fibula), transferred with its own blood supply intact. This type of graft provides immediate structural support and is especially well suited for defects larger than 6 centimeters.
The fibula can be cut and reshaped to match the natural curve of the jawbone, and in some cases, dental implants are placed into the transplanted bone during the same operation. This “jaw in a day” approach allows patients to begin eating with a temporary prosthesis relatively quickly. Oral feeding generally resumes two to three weeks after facial reconstruction.
If the fibula isn’t a viable option due to vascular issues or other concerns, surgeons can use bone from the hip or shoulder blade instead. These alternatives can also support dental implants, though the available bone may be thinner. The recovery process after jaw reconstruction is substantial, involving adjustments to eating, speaking, and facial appearance, but modern techniques have made functional outcomes considerably better than they were a generation ago.
Long-Term Outlook
Ameloblastoma is not life-threatening in the vast majority of cases, but it demands long-term follow-up regardless of treatment type. Recurrence can happen years or even decades after the initial surgery, so regular imaging (typically panoramic X-rays or CT scans) is standard practice for many years. Multicystic tumors carry the highest recurrence risk, with a rate of about 38% after conservative surgery and 11% after radical surgery. Recurrences are treated with additional surgery, and the approach typically becomes more aggressive with each recurrence to reduce the chance of the tumor returning again.